StemoniX
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | Grant | |
N/A | $523k | Debt | |
$6.0m | Series A | ||
N/A | $1.5m | Debt | |
N/A | $305k | Debt | |
N/A | $4.4m | Early VC | |
N/A | $1.4m | Debt | |
$14.0m | Series B | ||
N/A | N/A | - | |
N/A | Merger | ||
Total Funding | $24.4m |
Recent News about StemoniX
EditStemoniX specializes in creating human organoid models and advanced analytical algorithms to accelerate drug discovery and reduce development costs. The company partners with leading biopharma, academic, and government institutions to provide functional models, expert services, and actionable results. StemoniX's core offerings include off-the-shelf and custom disease models, as well as their Assay AnalytiX platform, which combines human biology and artificial intelligence to deliver deeper insights and faster returns from experiments. The company serves clients in the pharmaceutical and biotechnology sectors, focusing on improving the efficiency and effectiveness of drug development processes. StemoniX generates revenue through the sale of its organoid models, analytical services, and custom research solutions.
Keywords: human organoid models, drug discovery, AI analytics, biopharma partnerships, disease models, Assay AnalytiX, iPSC, cardiomyocytes, neurons, toxicology studies.